Last reviewed 2026-04-22 · How we verify

Carboplatin + Gemcitabine

Carboplatin + Gemcitabine is a Chemotherapy combination (platinum agent + nucleoside analog) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Non-small cell lung cancer, Ovarian cancer, Breast cancer.

Carboplatin and gemcitabine together work as a chemotherapy combination that damages cancer cell DNA and inhibits nucleotide synthesis to kill rapidly dividing cells.

Carboplatin and gemcitabine together work as a chemotherapy combination that damages cancer cell DNA and inhibits nucleotide synthesis to kill rapidly dividing cells. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.

At a glance

Mechanism of action

Carboplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication and transcription. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, disrupting synthesis. The combination exploits complementary mechanisms to enhance cytotoxicity against cancer cells.

Approved indications

• Non-small cell lung cancer
• Ovarian cancer
• Breast cancer
• Pancreatic cancer
• Bladder cancer

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Nausea/vomiting
• Fatigue
• Nephrotoxicity
• Peripheral neuropathy
• Alopecia

Key clinical trials

• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
• Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
• Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Carboplatin + Gemcitabine CI brief — competitive landscape report
• Carboplatin + Gemcitabine updates RSS · CI watch RSS
• AstraZeneca portfolio CI

Frequently asked questions about Carboplatin + Gemcitabine

Related

• Drug class: All Chemotherapy combination (platinum agent + nucleoside analog) drugs
• Manufacturer: AstraZeneca — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Non-small cell lung cancer
• Indication: Drugs for Ovarian cancer
• Indication: Drugs for Breast cancer
• Compare: Carboplatin + Gemcitabine vs similar drugs
• Pricing: Carboplatin + Gemcitabine cost, discount & access